Evolving roles of oncology pharmacists in Singapore: A survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre

Journal of Oncology Pharmacy Practice

Volumn 14, Issue 1, 2008, Pages 23-29

  Chan, Alexandre ^a,b   Shih, Vivianne ^b   Chew, Lita ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Chemotherapy; Nausea; Vomiting

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DOMPERIDONE; GEMCITABINE; METOCLOPRAMIDE; NAVELBINE; NEUROKININ 1 RECEPTOR ANTAGONIST; SEROTONIN ANTAGONIST; ANTINEOPLASTIC AGENT;

AGE; ANXIETY; ARTICLE; BOLUS INJECTION; CANCER CENTER; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; DRUG UTILIZATION; HEALTH SURVEY; HUMAN; NAUSEA; NEOPLASM; PATIENT COUNSELING; PHARMACIST; PHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SELF CONCEPT; SEX DIFFERENCE; SINGAPORE; TREND STUDY; AMBULATORY CARE; CLINICAL PRACTICE; INFORMATION PROCESSING; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; PHYSICIAN; PROFESSIONAL STANDARD; PSYCHOLOGICAL ASPECT; STANDARD; VOMITING;

AMBULATORY CARE; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DATA COLLECTION; GUIDELINE ADHERENCE; HUMANS; NAUSEA; NEOPLASMS; PATIENT EDUCATION AS TOPIC; PHARMACEUTICAL SERVICES; PHARMACISTS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PROFESSIONAL ROLE; SINGAPORE; VOMITING;

EID: 42949092016     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155207084009     Document Type: Article

References (33)

1. Ministry of Health Singapore. Health Facts Singapore. Available at: http://www.moh.gov.sg/corp/publications/statistics/principal.do. Accessed February 12, 2007.
2. Bloechl-Daum B., Deuson RR, Mavros P., et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006; 24(27): 4472-8.
3. Warr D. Standard treatment of chemotherapy-induced emesis. Support Care Cancer 1997; 5(1): 12-6.
4. Dodd M., Onishi K., Dibble S., et al. Differences in nausea, vomiting and retching between younger and older outpatients receiving cancer chemotherapy. Cancer Nursing 1996; 19(3): 155-161.
5. Goodman M. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting. Oncology Nursing Forum 1997; 24(7 Suppl.): 20-32.
6. Ouwerkerk J. Cancer therapy-induced emesis: The nurse's perspective. Eur J Cancer Care 1994; 3(1): 18-25.
7. Osoba D., Zee B., Pater J., et al. Determinants of postchemotherapy induced nausea and vomiting in patients with cancer. Quality of Life and Symptom Control committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997; 15: 116-123.
8. Molassiotis A., Yam BMC, Yung H., et al. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 2002; 10: 139-45.
9. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol 2006; 24(18): 2932-47.
10. NCCN Clinical Practice Guidelines in Oncology. Antiemesis v1 2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/ antiemesis.pdf. Accessed February 12, 2007.
11. ASHP Commission on Therapeutics. ASHP Therapeutics guidelines on the pharmacologic management of nausea and vomiting. Am J Health Syst Pharm 1999; 56(8): 729-764.
12. Grunberg S., Deuson R., Mavros P., et al. Incidence of chemotherapy induced nausea and emesis after modern antiemetics perception versus reality. Cancer 2004; 100(10): 2261-8.
13. Hichok JT, Roscoe JA, Morrow GR, et al. Nausea and emesis remain significant problem of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: A Univeristy of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 2003; 97(11): 2880-6.
14. Liekweg A., Westfeld M., Jaehde U. From oncology pharmacy to pharmaceutical care: New contributions to multidisciplinary cancer care. Support Care Cancer 2004; 12: 73-9.
15. Wu HT, Graff LR, Yuen CW Clinical pharmacy in an inpatient leukemia and bone marrow transplant service. Am J Health-Syst Pharm 2005; 62: 744-7.
16. Shah S., Dowell J., Greene S. Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting. Ann Pharmacother 2006; 40: 1527-33.
17. Dranitsaris G., Warr D., Puodziunas A. A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. Support Care Cancer 1995; 3(3): 183-9.
18. Dranistsaris G., Leung P., Warr D. Implementing evidence based antiemetic guidelines in the oncology setting: Results of a 4-month prospective intervention study. Support Care Cancer 2001; 9(8): 611-8.
19. Berard CM, Mahoney CD Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting. Am J Health Syst Pharm 1995; 52: 1879-85.
20. Bogden PE, Koontz LM, Williamson P., et al. The physician and pharmacist team. An effective approach to cholesterol reduction. J Gen Intern Med 1997; 12: 158-64.
21. Borenstein JE, Graber G., Saliel E., et al. Physician-pharmacist co-management of hypertension: A randomized, comparative trial. Pharmacotherapy 2003; 23: 209-16.
22. Whitmer KM, Pruemer JM, Nahleh ZA, et al. Symptom management needs of oncology outpatients. J Palliat Med 2006; 9(3): 628-30.
23. Herrstedt J., Aapro MS, Smyth JF, et al. Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 1998; 6(3): 204-14.
24. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence. J Clin Oncol 2000; 18(19): 3409-3422.
25. Vardy J., Chiew KS, Galica J., et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 2006; 94(7): 1011-5.
26. Gridelli C., Perrone F., Gallo C., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-72.
27. Goedhals L., Heron JF, Kleisbauer JP, et al. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: A double-blind, placebo-controlled, comparative study. Ann Oncol 1998; 9(6): 661-6.
28. Gandara DR, Harvey WH, Monaghan GG, et al. Delayed emesis following high-dose cisplatin: A double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer 1993; 29A(Suppl 1): S35-8.
29. Aapro MS, Thuerlimann B., Sessa C., et al. Swiss Group for Clinical Cancer Research. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 2003; 14(2): 291-7.
30. De Wit R., Schmitz PI, Verweij J., et al. Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained. J Clin Oncol 1996; 14(2): 644-51.
31. De Wit R., van der Berg H., Burghouts J., et al. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer 1998; 77(9): 1487-91.
32. The Italian Group for Antiemetic Research. Transferability to clinical practice of the results of controlled clinical trials: The case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann Oncol 1998; 9(7): 759-765.
33. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282(15): 1458-65.